Aura Biosciences gets $30M round; investors include Termeer estate
Cancer drug startup Aura Biosciences says it ’s planning to hire more employees after securing $30 million in new financing from a group of investors that includes the estate of Genzyme's longtime CEO Henri Termeer.
The Cambridge company said Thursday that the Series C round, which was led by UK-based Arix Bioscience and a foundation affili ated with Danish drugmaker Lundbeck, would fund the development of its lead drug for ocular melanoma. All of Aura’s existing investors participated in the…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Max Stendahl Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Denmark Health | Health Management | Melanoma | Skin Cancer